Leap Therapeutics (LPTX)

• Market cap: $112M
• 1 day: 0.69%
• 5 days: -5.52%
• 1 month: 15.48%
• 3 months: 12.36%
• 6 months: 54.79%
• Year to date: -37.69%
• 1 year: -26.70%
• 5 years: -71.19%
• 10 years: -96.30%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Employees: 54

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

109% more call options, than puts

Call options by funds: $23K | Put options by funds: $11K

32% more capital invested

Capital invested by funds: $28.7M [Q2] → $37.9M (+$9.15M) [Q3]

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

4% more funds holding

Funds holding: 45 [Q2] → 47 (+2) [Q3]

0.22% more ownership

Funds ownership: 38.3% [Q2] → 38.52% (+0.22%) [Q3]

31% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5.50 89% upside
• Avg. target: $5.50 89% upside
• High target: $5.50 89% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 27% 1-year accuracy 46 / 173 met price target

89% upside $5.50

Buy Reiterated

15 Nov 2024